{"id":7585,"date":"2019-10-22T16:39:48","date_gmt":"2019-10-22T20:39:48","guid":{"rendered":"https:\/\/www.med.unc.edu\/neurology\/?page_id=7585"},"modified":"2023-09-22T13:53:27","modified_gmt":"2023-09-22T17:53:27","slug":"memory-and-cognitive-disorders-research","status":"publish","type":"page","link":"https:\/\/www.med.unc.edu\/neurology\/divisions\/memory-and-cognitive-disorders-1\/memory-and-cognitive-disorders-research\/","title":{"rendered":"Dementia Research Studies"},"content":{"rendered":"
Research is an important component of the work performed by the Memory Disorders Clinic at the University of North Carolina Chapel Hill. In addition to providing important clinical care to the North Carolina community, the Memory Disorders Clinic coordinates a number of research studies investigating memory disorders.
\n<\/div><\/div>\n
<\/p>\n
ALLFTD is a multisite observational research study aimed at understanding how frontotemporal lobar degeneration (FTD or FTLD) syndromes affect the brain. This research study has a longitudinal option, consisting of one study visit a year (including fasting blood draw, cognitive testing, clinical assessment, questionnaires, MRI brain imaging and optional lumbar puncture and genetic testing) for up to five years, and a biofluid option, which is a shorter one-time visit.<\/p>\n
Frontotemporal degeneration syndromes may include behavioral variant FTD (bvFTD), Progressive Supranuclear Palsy (PSP), semantic variant or nonfluent variant primary progressive aphasia (svPPA or nfvPPA), or FTD with Amyotrophic Lateral Sclerosis (FTD\/ALS).<\/p>\n
To be eligible for the study, you must:<\/p>\n
If you are interested in learning more about the study, please email us at ALLFTD@neurology.unc.edu<\/a> or call us at 919-843-8673. You can also learn more at the\u00a0ALLFTD website, https:\/\/www.allftd.org\/<\/a>.<\/p>\n<\/div>\nThe SHIMMER Study from Cognition Therapeutics for Lewy Body Disease (COG1201)<\/strong><\/span> To be eligible for the 6-month study, the following criteria must be met:<\/p>\n If you are interested in learning more about the study, please contact our study coordinator Latorius Adams at adamsl@neurology.unc.edu<\/a> or (919) 962-2900. To be eligible for the study, you must:<\/span><\/p>\n For questions or to participate in the study, please email us at DLBC@neurology.unc.edu<\/a> or call us at 919-843-8673.<\/span><\/p>\n Learn more about Lewy Body Dementia here: ºÚÁÏÍø Neurology, Lewy Body Dementia<\/a><\/p>\n<\/div>\nDuke-ºÚÁÏÍø Alzheimer's Disease Research Center's Memory & Aging Study<\/strong><\/span> The ADRC aims to catalyze and support research, innovations in clinical care and academic work force development (with North Carolina Central University, East Carolina University and ºÚÁÏÍø Pembroke as partner institutions) in this field. The ultimate purpose is to reduce the burden of Alzheimer\u2019s disease and related dementias regionally and nationally. The outstanding scientific environment at both institutions enables novel research to identify effective methods of prevention and\/or early intervention, and to reduce racial and urban\/rural disparities associated with dementia.<\/span><\/p>\n If you are interested in learning more about the study, please contact our study coordinator Latorius Adams at\u00a0adamsl@neurology.unc.edu<\/a>\u00a0or (919) 962-2900.<\/span><\/p>\n Learn more about Duke-ºÚÁÏÍø ADRC and the Alzheimer’s Disease Research Center’s Memory & Aging Study here<\/a>.<\/p>\n<\/div>\nNC Registry for Brain Health in Aging<\/strong><\/span> The NC Registry for Brain Health is the first registry of its kind in the State of North Carolina. The Registry is designed to increase awareness of Alzheimer’s disease and related disorders and to connect North Carolinians of all ages to research opportunities designed to improve brain health.<\/span><\/p>\n When you join the NC Registry for Brain Health, you will learn about research taking place at Duke University, East Carolina University, North Carolina A&T State University, The University of North Carolina at Chapel Hill, and Wake Forest School of Medicine.<\/span><\/p>\n All adults ages 18 or older are encouraged to join the registry.\u00a0 When you join, you will receive a welcome email followed by a quarterly email newsletter which provides the most recent information about brain health research.\u00a0 In addition, you will receive the occasional email which will provide you with information about a study opportunity. If you are interested in participating, you will contact the study coordinator listed in the email.\u00a0<\/span><\/p>\n To learn more and to join the registry please go to:\u00a0<\/span>https:\/\/ncbrainhealth.org\/<\/span><\/a>\u00a0<\/span><\/p>\nAn oral medication, CT1812, is being investigated for the potential treatment of Dementia with Lewy Bodies (DLB). The purpose of this clinical trial is to learn about the safety of CT1812 and how well your body tolerates a once-a-day dose of CT1812. The study will also test how well CT1812 treats symptoms of mild to moderate DLB. Eligible participants will have a 2 out of 3 (66.6%) chance of receiving CT1812 and a 1 out of 3 (33.3%) chance of receiving placebo (sugar pill).<\/p>\n
\n
\n<\/div>\nDLBC - Dementia with Lewy Bodies Consortium<\/strong><\/span>DLBC is an observational research study aimed at learning more about Dementia with Lewy Bodies. The trial focuses on identifying biomarkers associated with the disease. DLBC consists of one research visit approximately once a year for up to 5 years, which includes a lumbar puncture or spinal tap, fasting blood draw, brain imaging (MRI and DaTScan), cognitive testing, a clinical assessment, and questionnaires.\u00a0<\/span><\/p>\n
\n
The Duke University and the University of North Carolina Alzheimer\u2019s Disease Research Center (Duke-ºÚÁÏÍø ADRC) brings together leading researchers in Alzheimer\u2019s disease and related dementias across two major research institutions.<\/span><\/p>\n
<\/p>\n